Our collaboration with SRI is yielding some new public data sets that leverage the small molecules and TB data collected in CDD with the expertise in pathways databases. Dr. Malabika Sarker has completed curation of target gene links, pathways, protein structures, references and in vivo essentiality information for all leads and drugs for which we initially had TB target information. Now we have links to KEGG, TBDB, Pubmed, PDB etc.
The “leads and targets” protocol can be combined with the “drugs and targets” protocol to result in over 700 molecules and can be found listed under TB drugs and leads with targets
The set of 314 “in vivo essential targets” is perhaps the first public dataset in CDD which does not have small molecule content included. But it provides in one location for the first time gene, pathway and protein links for all of them. This database is TB target database for In vivo essential genes.
These should be useful additions to our TB databases and could be useful finding similar structures that may mimic the molecules active against a particular target.
Tag(s):
Other posts you might be interested in
View All Posts
CDD Insights
3 min
January 4, 2012
Collaboration as the key to turning around the drug discovery business (Part 6) - Technology can make things easier
Read More
Events
2 min
August 10, 2010
CDD Presents Two Talks & Two Posters at ACS Fall 2010
Read More
CDD Blog
3 min
March 17, 2020
Recorded Webinar: PROTAC — Developing New Therapies through Targeted Protein Degradation
Read More

